Advanced glycation and the immune system: Stimulation, inhibition or both?

European Journal of Clinical Investigation

Volumn 31, Issue 12, 2001, Pages 1015-1018

  Glorieux, G ^a   Vanholder, R ^a   Lameire, N ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINO ACID; AMINOGUANIDINE; CARBOXYETHYLLYSINE; DIMER; FRUCTOSE LYSINE; GLYOXAL DERIVATIVE; IMIDAZOLE DERIVATIVE; LACTOFERRIN; LYSINE DERIVATIVE; LYSOZYME; METHYLGLYOXALLYSINE; NITRIC OXIDE SYNTHASE; PENTOSIDINE; PYRRALINE; PYRROLE DERIVATIVE; SCHIFF BASE; SUPEROXIDE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

AGING; AORTA WALL; ATHEROSCLEROTIC PLAQUE; BURN; CELL AGGREGATION; CELL FUNCTION; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULOSCLEROSIS; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNITY; INJURY; KIDNEY DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; MONOCYTE; NEUROPATHY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEUM MACROPHAGE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RETINOPATHY; SEPSIS; UREMIA; VASCULAR DISEASE;

ANIMALS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNE SYSTEM; NEUTROPHILS;

EID: 0035791503     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00910.x     Document Type: Note

References (48)

1. Bernheim J, Rashid G, Gavrieli R, Korzets Z, Wolach B. In vitro effect of advanced glycation end-products on human polymorphonuclear superoxide production. Eur J Clin Invest 2001;31:1064-1069.
2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21.
3. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994;46:216-22.
4. Thorpe SR, Baynes JW. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9:69-77.
5. Friedman EA. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 1999;14 (Suppl. 3):1-9.
6. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7:1198-206.
7. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992;41 (Suppl. 2):36-41.
8. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-81.
9. Patel SR, Koenig RJ, Hsu CH. Effect of Schiff base formation on the function of the calcitriol receptor. Kidney Int 1996;50:1539-45.
10. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N et al. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-52.
11. Sakata S, Takahashi M, Kushida K, Tachikawa Y, Takebagashi S, Nagai R et al. The relationship between pentosidine and hemodialysis-related connective tissue disorders. Nephron 1998;78:260-5.
12. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-8.
13. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, Nguyen AT, Canteloup S et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-32.
14. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-8.
15. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995;1:1057-61.
16. Verbeke P, Perichon M, Friguet B, Bakala H. Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells. Biochim Biophys Acta 2000;1502:481-94.
17. Ramirez R, Bedoya FJ, Chiara MD, Sobrino F. Inhibitory effect of albumin-derived advanced glycosylation products on PMA-induced superoxide anion production by rat macrophages. Life Sci 1997;60:2279-89.
18. Liu BF, Miyata S, Kojima H, Uriuhara A, Kusinoki H, Suzuki K et al. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 1999;48:2074-82.
19. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521-8
20. Cohen G, Rudnicki M, Horl WH. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int 2001;59 (Suppl. 78):S48-S52.
21. Sengoelge G, Fodinger M, Skoupy S, Ferrara I, Zangerle C, Rogy M et al. Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Kidney Int 1998;54:1637-51.
22. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Ulassara H et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010-4.
23. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V et al. Advanced glycosylation endproduct-specific receptors on human and rat T- lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993;178:2165-72.
24. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992;90:439-46.
25. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546-8.
26. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann NY Acad Sci 1995;748:562-70.
27. Rashid G, Luzon AA, Korzets Z, Klein O, Zeltzar E, Bernheim J et al. The effect of advanced glycation end-products and aminoguanidine on TNFalpha production by rat peritoneal macrophages. Perit Dial Int 2001;21:122-9.
28. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91:9436-40.
29. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991;39:320-7.
30. Simms HH, Frank MM, Quinn TC, Holland S, Gaither TA. Studies on phagocytosis in patients with acute bacterial infections. J Clin Invest 1989;83:252-60.
31. Solomkin JS, Cotta LA, Ogle JD, Brodt JK, Ogle CK, Satoh PH et al. Complement-induced expression of cryptic receptors on the neutrophil surface: a mechanism for regulation of acute inflammation in trauma. Surgery 1984;96:336-44.
32. Moore FD Jr, Davis C, Rodrick M, Mannick JA, Fearon DT. Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med 1986;314:948-53.
33. Dhondt A, Vanholder R, Glorieux G, Waterloos MA, De Smet R, Lesaffer G et al. Vitamin E-bonded cellulose membrane and hemodialysis bioincompatibility: absence of an acute benefit on expression of leukocyte surface molecules. Am J Kidney Dis 2000;36:1140-6.
34. Dhondt AW, Vanholder RC, Waterloos MA, Glorieux GL, Ringoir SM. Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. Nephron 1996;74:342-8.
35. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58.
36. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999;55:1945-51.
37. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross- linking. Science 1986;232:1629-32.
38. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999;48:1308-15.
39. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
40. Raskin P, Cattran D, Williams M, Wuerth JP, Cartwright K and the ACTION 1 Investigator Group. Pimagedine (PG) reduces progression of retinopathy and lowers lipid levels in patients with type 1 Diabetes Mellitus (DM). J Am Soc Nephrol 1999;10:179A(Abstract).
41. Miyata T, Kurokawa K, van Ypersele dS. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000;11:1744-52.
42. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251-8.
43. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman EA, Kaufman AM et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519-22.
44. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-7.
45. Hricik DE, Wu YC, Schulak A, Friedlander MA. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant 1996;10:568-73.
46. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997;52:1645-50.
47. Henle T, Deppisch R, Beck W, Hergerell O, Hansch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-75.
48. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'. Kidney Int 1999;55:2487-92.